Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.

NCT00617461 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

NCT NCT00617461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00617461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.
Lead sponsor
XenoPort, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
July 31, 2009
Enrollment
96 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

neuralgia, postherpetic